Secretagogues reliably raise GH and IGF-1 in short human studies. What they do to body composition, performance or long-term health in healthy adults is far less established, and appetite, water retention and glucose effects are the recurring practical concerns.
Key points
- CJC-1295 produced sustained increases in GH and IGF-1 in early human pharmacokinetic work.
- Reviews of secretagogue safety describe generally tolerable short-term profiles with limited long-term data.
- Ghrelin-receptor agonists (GHRP-2, GHRP-6) increase appetite and can raise cortisol and prolactin at higher doses.
What the literature shows
Human dosing studies of CJC-1295 reported dose-dependent, prolonged elevation of GH and IGF-1 without serious adverse events over the short observation windows used.
A published review of GH secretagogues concluded that available data support short-term tolerability but that efficacy claims for body composition and performance in healthy people are not adequately supported.
Raised IGF-1 signalling is the mechanistic basis for concerns about tissue growth and insulin resistance; those concerns are extrapolated rather than demonstrated in this population.
What remains unknown
- No long-term outcome data in healthy adults using these peptides for physique or performance goals.
- Optimal or safe dosing outside the studied ranges is unestablished.
- Purity and peptide identity in the unregulated market are largely unquantified.
Safety and monitoring implications
- Glucose tolerance can worsen; anyone with insulin resistance or a family history of diabetes should treat this as a live risk.
- Carpal-tunnel type symptoms, oedema and joint discomfort are commonly reported with GH-axis elevation.
- Any personal or family history of malignancy is a strong reason for medical consultation first.
Cited literature
- 1.Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. Find on PubMed
- 2.Sigalos JT, Pastuszak AW. (2018). The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews. Find on PubMed
Community reports
Anecdotal — not scientific evidence
Lived experience is valuable context and often surfaces problems before the literature does. It is also uncontrolled, unverified and subject to bias, so it never overrides published findings here.
Aggregated community threads
MixedSleep quality and appetite changes are the most consistently reported subjective effects; physique changes are usually described as slow and modest.
Buying GH secretagogues in Australia: what to check first
APEDRA does not sell GH secretagogues or any other product, and takes no commission from suppliers. If you are researching where to buy it, the biggest practical risk is not the compound itself but what is actually in the bottle: under-dosing, substitution with a different compound, and contamination are all documented in independent testing of online research chemicals.
- Ask for a batch-specific third-party lab report (HPLC/mass spectrometry), not a generic certificate.
- Check independent review platforms, not only reviews hosted on the seller's own site.
- Read the shipping, returns and refund policies before ordering.
- Be wary of prices far below the market or exaggerated results claims.
Compare Australian vendors independently · how we assess suppliers
Terms used here are defined in our glossary, and the evidence-grading scale explains what this analysis's grade means. If you believe something here is wrong, tell us.
This analysis is educational. It is not medical advice, a dosing recommendation, or an endorsement of use. Speak with a qualified medical practitioner about your circumstances.